Loading...

Article: The Promise and Peril of ChatGPT in Healthcare and Pharma Marketing

2023-06-02T21:12:20+00:00Thought Leadership|

Since its release on November 30, 2022, ChatGPT has generated buzz across all corners of the internet and within every industry. The technology is likely to have in impact in healthcare, the life sciences, and marketing. Precision’s Marty Samples and others weigh in on its uses in healthcare and the life sciences, including its potential and potential pitfalls.

READ THE ARTICLE HERE!

Conference: Meeting on the Med, 2023

2023-06-02T21:01:53+00:00Events, Thought Leadership|

Precision will be at this year’s Meeting on the Med, April 12-14, 2023, in Barcelona, Spain. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization for cell and gene therapies.

Connect with our Advanced Therapy experts

  • Visit us through any of the numerous networking opportunities at Meeting on the Med 23′
  • Be sure to attend the ADVANCE sponsored workshop on April 12, 2023, at 4:45PM – 5:30PM CET |Location: Hotel Arts Barcelona (BioCentriq Ballroom: Gaudi 3)

You can register for Meeting on the Med below:

REGISTER HERE

(more…)

Article: The FDA and AAV-Based Gene Therapy Safety: What You Should Know

2023-07-11T13:42:41+00:00Thought Leadership|

Over the last couple of years, we have witnessed the tremendous potential of adeno-associated virus (AAV)-based gene therapies. However, there have been a few high-profile safety issues that have occurred, including deaths associated with AAV vector gene therapies that have raised safety concerns among the public and regulators. Don’t miss this great primer on AAV-based gene therapies by Precision’s Deb Phippard and Phil Cyr, including basic background on the vectors, safety concerns, strategies to mitigate safety issues, and recent FDA safety meetings.

CLICK HERE to read the full article

Article: What Does Game Theory Teach Us About Cell and Gene Therapy Coverage?

2023-05-29T19:26:47+00:00Thought Leadership|

Cell and gene therapy (CGT) presents a high reward and risk proposition on multiple levels involving many stakeholders, including patients and their family members, conventional risk-bearing healthcare insurers, large employers who are self-insured, and CGT innovators. Precision’s Liz Turner, Philip L. Cyr, and Ross Maclean analyze some of the risks and rewards for several stakeholders, and explain how the classical game theory paradox, the “prisoner’s dilemma,” can be used to maximize the potential rewards for everyone and minimize the potential risks of acting in one’s own self-interest.

CLICK HERE to read the full article.

White Paper: What’s Next for Cell and Gene Therapies in 2023 and Beyond

2023-05-29T18:48:48+00:00Thought Leadership|

The cell and gene therapy (CGTx) sector has flourished in recent years due to continued investor confidence. However, the present downturn in public markets has negatively affected that confidence, raising questions about the sector’s prospects for 2023 and beyond.

This white paper is based on a panel discussion at the Cell & Gene Meeting on the Mesa (October 11, 2022), sponsored by Precision ADVANCE, focusing on the future of advanced therapies. The panel included insights from the following industry leaders:

  • Anshul Mangal: President (Project Farma & Precision ADVANCE)
  • Stewart Abbot: Chief Scientific Officer (Turnstone Biologics)
  • Laura Lande-Diner: Chief Business Officer (Satellite Bio)
  • Robert Peters: Chief Scientific Officer (Ensoma)
  • Deborah Phippard: Chief Scientific Officer (Precision For Medicine)

DOWNLOAD THE WHITEPAPER HERE!

Conference: Gene Therapy for Rare Disorders, 2023

2023-05-29T16:10:13+00:00Events, Thought Leadership|

Precision will be at this year’s Gene Therapy for Rare Disorders on March 20-23, 2023, in Boston, MA. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization for gene therapies.

Speaking Engagements
Detailed descriptions for each speaking engagement are included below. 

  • Precision ADVANCE will have a plenary speaking position on March 21, 2023, 8:30 – 9:00 am.
  • Project Farma will be facilitating a plenary panel discussion ” Current Trends in Technical Operations for Rare Disorders” on March 21, 2023, 10:45 – 11:15 am.
  • Project Farma’s Tony Khoury (EVP, Project Farma) will be joining the Manufacturing track panel discussion, “Capacity versus Capability – Moving Towards Innovative Manufacturing Processes,” on March 21, 2023, 11:15 – 11:45 am.
  • Precision ADVANCE will hold a drinks reception on March 21, 2023, at 6:10 pm in the Grand & Liberty Ballroom.

Connect with our Advanced Therapy experts

  • Visit us at booth 13 in the exhibition area
  • Schedule in-person or virtual meetings by clicking here: https://bit.ly/precisionmedicinegrp
  • Attend our ADVANCE-sponsored Drinks Reception on March 21, 2023, at 6:10 PM ET

(more…)

Weathering the Storm: Cell and Gene’s Economic Downturn

2023-02-21T20:37:32+00:00Thought Leadership|

After record-setting milestones in fundraising over the past two years, the advanced therapy investment landscape is experiencing a natural correction. Precision’s Anshul Mangal and Dr. James M. Wilson outline in this The Medicine Maker article how industry leaders can ensure the advancement of innovative treatments for patients with #rarediseases by consolidating investments and prioritizing partnerships with patient advocacy organizations.

READ THE ARTICLE HERE!

On Demand: Let’s Talk: Moving CGTx Clinical Development Forward in 2023

2023-05-29T15:19:40+00:00Events, Thought Leadership|

Sponsored by Precision ADVANCE, this Endpoints webinar will convene leading advanced therapy experts to discuss the future of CGTx clinical development. This discussion will be moderated by Teresa Pokladowski: Regional VP, Clinical Business Solutions (Precision for Medicine), and include insights from Kinnari Patel: President & COO (Rocket Pharmaceuticals), Suma Krishnan: Founder & President (Kystal Biotech), Dawn Buchanan: VP Clinical Operations (AffyImmune), and Ramona Repaczki-Jones: Executive Director, Commercial Treatment Center Operations, Cell Therapy (lovance Biotherapeutics, Inc).

(more…)

White Paper: State of the Union for Advanced Medicines

2023-02-21T16:33:26+00:00Thought Leadership|

The cell and gene therapy (CGTx) sector has flourished over the last 2 to 5 years due to continued investor confidence. However, the recent downturn in public markets has undermined that confidence.

This white paper is based on a panel discussion, sponsored by Precision ADVANCE, featuring insights from diverse industry perspectives on the current state of the CGTx sector; the investment landscape; scientific and technical advances; progress in drug development, manufacturing, regulatory, pricing, and reimbursement; and expected key trends in 2023 and beyond. Hosted by Endpoints News, the panel included insights from the following industry leaders:

  • Anshul Mangal: President (Project Farma & Precision ADVANCE)
  • Dave Greenwald: Vice President of Business Development (Deerfield Management)
  • Rajul Jain: Managing Director (Vida Ventures)
  • Joseph LaBarge: Chief Executive Officer (Apertura Gene Therapy)
  • Adrian Woolfson: Executive Chairman, President and Co-Founder (Replay Bio)
  • Phil Cyr: Executive Vice President (Precision Value & Health)

(more…)

Load More Posts